Orthopoxvirus-specific antibodies wane to undetectable levels one year after MVA-BN vaccination of at-risk individuals - van Leeuwen, Leanne P. M.; Shamier, Marc C.; Verstrepen, Babs E.; Götz, Hannelore M.; Schmitz, Katharina S.; Akhiyate, Najlae; Wijnans, Koen; Bogers, Susanne; van Royen, Martin E.; van Gorp, Eric C. M.; Koopmans, Marion P. G.; de Vries, Rory D.; et al. (medRxiv, 2024)
In response to the 2022-2023 mpox outbreak, widespread vaccination with modified vaccinia Ankara-Bavarian Nordic was initiated. Here, we demonstrate that orthopoxvirus-specific binding and MVA-neutralizing antibodies wane to undetectable levels one year post-vaccination in at-risk individuals without pre-existing immunity. Continuous surveillance is essential to understand the impact of declining antibody levels.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received funding from the European Union's funding program H2020 research and innovation program under grant agreement 101115188 and the Netherlands Organization for Health Research and Development (ZonMw) under grant agreement 10150022310035.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sera from two biobank protocols were used. Both protocols were approved by the Erasmus MC Medical Ethics Review Committee: the COVA study (MEC-2014-398) and the RestPlus study (MEC-2022-0675).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.